Updates

Author Details

Joe Pierce

November 25, 2020November 25, 2020
AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its ... Read more
November 23, 2020November 19, 2020
Don’t Let Alzheimer’s Disease Steal Thanksgiving

As exampled by the Pilgrims and the Indigenous people who graced the first Thanksgiving table, families in the United States gather each year to ... Read more
November 23, 2020November 23, 2020
Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial

Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection due to Porphyromonas gingivalis, a bacteria linked ... Read more
November 18, 2020November 18, 2020
Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity ... Read more
November 16, 2020November 12, 2020
Finding Nursing Home Placement for a Loved One With Alzheimer’s

In the early days of diagnosis and the early stages of Alzheimer’s disease, a caregiver is capable of sufficiently providing for their loved one. ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Author Details

Joe Pierce

Thanks! Please check your email for a confirmation email.

November 8, 2017November 8, 2017

Anavex ‘Cautiously Optimistic’ After Noting Cognitive Improvement in Alzheimer’s Treatment

News

Anavex Life Sciences says its Alzheimer’s drug candidate Anavex 2-73 may have a role in treating the disease. Data from a long-term extension trial, although small, indicated that the therapy improved cognitive and functional measures in patients. According to data ... Read more

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

Don’t Let Alzheimer’s Disease Steal Thanksgiving

Gum Disease Bacteria Found in Most Alzheimer’s Patients in Atuzaginstat Trial

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

Finding Nursing Home Placement for a Loved One With Alzheimer’s

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

National Family Caregivers Month Is a Chance to Spread Happiness

EMA Agrees to Review Biogen, Eisai Request for Aducanumab’s Approval

Awareness Month Activities Shine Spotlight on Alzheimer’s, Dementia

Infrastructure Is Needed to Support Familial Caregivers

Subscribe to our mailing list

Seth Rogen’s HFC ‘Game Show’ Raises $325K to Benefit Alzheimer’s Care

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

Embracing Happiness When Caring for a Loved One With Alzheimer’s

Simple Language Test May Predict Alzheimer’s Onset Years Before Symptoms Start

RetiSpec and Gentex Developing Technology to Detect Early Alzheimer’s

Caregivers Should Connect to Breast Cancer Awareness

First Patient Dosed in Phase 2 Trial of Bryostatin-1 in Long-term Use

GemVax Seeks Expanded Access for Mild Alzheimer’s for Planned GV1001 US Trial

The Reality of Death and Caregiving

Dosing Starts in Phase 2/3 Trial of Athira’s ATH-1017 for Alzheimer’s

Semorinemab Fails to Show Efficacy in Early Alzheimer’s Phase 2 Trial

Creating a Last Will and Testament to Care for a Loved One

$1.76M Grant to Support Trial of Jotrol, Form of Resveratrol, in Early Alzheimer’s

Mundane Errands Become Worthwhile Adventures With Alzheimer’s Disease

CDC Taps Alzheimer’s Association to Lead National Effort to Slash Dementia Risk

Sumifilam Lowers Levels of Multiple Biomarkers of Disease Activity, Trial Shows

Preventing Bias Against People With Alzheimer’s Disease

Specific Tau Protein Shows Potential as Blood Biomarker in Early Studies

Theme for World Alzheimer’s Month Is ‘Let’s Talk About Dementia’

The Dirty Secret Behind Caregiving

Phase 3 Trial of AXS-05 to Treat Agitation in Alzheimer’s Likely by Year’s End

First Patients Dosed in Annovis Bio’s ANVS401 Trial, Delayed Due to COVID-19

Part the Cloud Awards $24M to Researchers Studying Potential Alzheimer’s Treatments

Alzheimer’s Care During a Catastrophic Event

Technique That Opens Blood-Brain Barrier May Help Target Treatment, Study Says

Patients in Australian Trials of Anavex 2-73 May Continue Using Therapy, Agency Says

Caregivers Face Increased Health Risks Compared With Noncaregivers

GAIN Trial Reaches Milestone With 500 Patients Enrolled

AFA Awards $518K for Study of Neuroimmune Interactions in AD Onset, Progression

How to Support a Friend With Alzheimer’s and Their Family

AC Immune Moves Closer to Clinical Studies of Anti-TDP-43 Antibody